Chronic granulomatous disease: Single-center Spanish experience

Clin Immunol. 2020 Feb:211:108323. doi: 10.1016/j.clim.2019.108323. Epub 2019 Dec 9.

Authors

A Robles-Marhuenda¹, J Álvarez-Troncoso², R Rodríguez-Pena³, C Busca-Arenzana², E López-Granados³, F Arnalich-Fernández²

Affiliations

¹ Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain. Electronic address: aroblesmarhuenda@gmail.com.
² Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain.
³ Immunology Department, Hospital Universitario La Paz, Madrid, Spain.

PMID: 31830531
DOI: 10.1016/j.clim.2019.108323

No abstract available

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Bacterial Agents / therapeutic use
Antifungal Agents / therapeutic use
Bacterial Infections / diagnosis
Bacterial Infections / drug therapy
Bacterial Infections / etiology
Bacterial Infections / genetics
Child
Child, Preschool
Female
Granulomatous Disease, Chronic* / complications
Granulomatous Disease, Chronic* / diagnosis
Granulomatous Disease, Chronic* / genetics
Granulomatous Disease, Chronic* / therapy
Humans
Immunosuppressive Agents / therapeutic use
Immunotherapy
Infant
Male
Mutation
Mycoses / diagnosis
Mycoses / drug therapy
Mycoses / etiology
Mycoses / genetics
NADPH Oxidase 2 / genetics
NADPH Oxidases / genetics
Spain

Substances

Adrenal Cortex Hormones
Anti-Bacterial Agents
Antifungal Agents
Immunosuppressive Agents
CYBB protein, human
NADPH Oxidase 2
NADPH Oxidases
CYBA protein, human
neutrophil cytosolic factor 1